Evidence map›Paper›PMID 31479631›Full record

ArticleAnalytical biochemistry2019

Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.

Wei Zhou, Yiping Li, Jinhua Song, Chenglong Li

Open access · greenAbstract read
In one paragraph

Article in Analytical biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Novel Allosteric Effectors Targeting Human Transcription Factor TEAD.International journal of molecular sciences · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Wei ZhouDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States.
Yiping LiDepartment of Medicinal Chemistry, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Jinhua SongDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, United States.
Chenglong LiDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, 32610, United States; Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, FL, 32610, United States. Electronic address: lic@ufl.edu.
University of Florida · USXi'an Jiaotong University · CN

Funding

Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapyR01NS088437 · NINDS · UNIVERSITY OF FLORIDA · PI LI, CHENGLONG, YANG, YUHONG · 2015 to 2017
$1.3M
NINDS NIH HHS R01 NS088437
6 · The paper itself

Abstract

The Hippo signaling pathway controls cell-cell contact, cell proliferation, as well as organ size by integrating changes in the cellular microenvironment. In recent years, the pivotal role of Hippo signaling in cancers has been well recognized. Inhibition of the pathway promotes the translocation of the major Hippo pathway effectors, the yes-associated protein (YAP) and its paralog TAZ, to the nucleus, where they interact with the transcription factor family transcriptional enhancer associate domain (TEAD), thus coactivating the expression of downstream genes, leading to cell transformation, tissue overgrowth, and tumor development. Therefore, the interruption of the YAP-TEAD transcriptional complex represents a novel opportunity for the treatment of cancer. Here, we established a fluorescence polarization (FP)-based assay for the identification and evaluation of YAP-TEAD protein-protein interface (PPI) inhibitors at the YAP Ω-loop binding region of TEAD, which is also called interface 3 at the YAP-TEAD binding surface. Furthermore, a patented small molecule (Patent-22) was evaluated by the FP assay, which confirmed that it was a YAP-TEAD PPI inhibitor at interface 3. Possessing great application value, this FP method is reliable, robust, and economical for inhibitor assessment and drug discovery.

Indexed as

PeptidesSmall Molecule LibrariesCell Cycle ProteinsCrystallography, X-RayFluorescence PolarizationHumansModels, MolecularMolecular StructureProtein BindingTranscription FactorsCell Cycle ProteinsPeptidesSmall Molecule LibrariesTranscription FactorsYY1AP1 protein, humanCyclic peptideDrug discoveryFluorescence polarization (FP)Hippo signaling pathwayK(i)Protein–protein interaction (PPI)Small molecule inhibitorTEADYAPΩ-loop

Identifiers

PMID31479631
PMCPMC6800033
OpenAlexW2971323672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.